Financial

Aspen’s comparable revenue increases by 12% to R35.4 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical company in the southern hemisphere, has announced positive results for the year ended 30 June 2016 notwithstanding economic pressures and currency weaknesses.   Stephen Saad, Aspen Group Chief Executive said, “The positive results underpin the strong foundation set which the business will build on in the 2017 financial year. The recent transactions, with a focus on anaesthetics which has been identified as a key therapeutic category for the Group’s strategic development plans, will further strengthen Aspen’s presence in the hospital sector. The International business remained the largest contributor to Group revenue and delivered strong comparable revenue growth. Manufacturing revenue from South Africa’s Active Pharmaceutical Ingredients (“APIs”) and finished dose forms showed pleasing growth of 52% and 69% respectively. Asia Pacific recorded a 11% comparable revenue increase to R7,4 billion, with Japan leading Asia’s 29% increase in sales. Gross revenue in sub-Saharan Africa increased 18% to R3,3 billion.”   GROUP PERFORMANCE Comparable revenue increased by 12% to R35.4 billion. Comparable normalised operating profit before amortisation, adjusted for specific non-trading items improved by 9% to R9.4 billion. Comparable normalised headline earnings per share rose 15% to 1222 cents. A dividend of 248 cents per ordinary share was declared.   As reported in the interim results, the factors set out below have significantly affected comparability with the results of the prior year and need to be considered when assessing performance for the 2016 financial year: The completion on 31 August 2015 of the divestment of the generics business conducted in Australia as well as certain branded products distributed in Australia to Strides group companies, the related termination of license arrangements in Australia and the completion on 1 October 2015 of the divestment of a portfolio of products distributed in South Africa to Litha Pharma (collectively “the Divestments”). The Divestments gave rise to a pre-tax profit on disposal of R1,6 billion. However, as a consequence of the timing of these transactions, the contribution to the trading results by the Divestments is substantially reduced in the 2016 financial year. In the period from 1 July 2015 until the effective date of divestment, revenue from the Divestments was R0,2 billion whereas revenue from the Divestments for the year ended 30 June 2015 was R1,8 billion.   The economic situation in Venezuela deteriorated over the year to 30 June 2016 and the Venezuelan authorities have increasingly limited authorisations to pay for pharmaceutical imports using the official DIPRO rate during this period of between Venezuelan Bolivar (“VEF”) 6,30 and 10,00 per US Dollar (“USD”). As a consequence of the limited payment approvals and the uncertain economic and political situation in Venezuela, before reporting the interim results for the 6 months ended 31 December 2015 , the Group concluded that it would be more appropriate to apply the DICOM exchange rate (VEF628.34 per USD at 30 June 2016) to report the Venezuelan business’ financial position, results of its operations and cash flows for the year ended 30 June 2016. This has resulted in a one-off currency devaluation loss on foreign denominated liabilities of R870 million.   The profit arising from the Divestments, the currency devaluation loss and the hyperinflationary adjustments relating to Venezuela are excluded, in addition to other specific non-trading items, in determining normalised performance. In order to provide meaningful comparability of the financial performance of the ongoing underlying business, a comparable measure has been determined by removing the contribution from the Divestments and including the results of Aspen’s business in Venezuela translated at VEF628.34 per USD in the prior reporting period.   The key performance measures for the Group for the year ended 30 June 2016 and the percentage change from the prior year are summarized as follows:     Revenue   Operating profit before amortisation   HEPS**   Comparable normalised*** R35,4 billion +12% R9,4 billion* +9% 1 222,0 cents +15% Normalised R35.6 billion -2% R9,5 billion* +3% 1 263,7 cents +10% Unadjusted R35,6 billion -2% R9,6 billion +7% 889.0 cents -23% * operating profit before amortisation, adjusted for specific non-trading items ** headline earnings per share *** The comparable information has been derived from the reviewed financial information and has not been reported on by Aspen’s auditors. This information has been prepared for illustrative purposes only and is the responsibility of the Board of Directors of Aspen   INTERNATIONAL BUSINESS The International Business increased comparable revenue 19% to R18,9 billion and grew comparable operating profit before amortisation, adjusted for specific non-trading items (“EBITA”), 15% to R5,9 billion.   Commercial revenue from pharmaceutical product sales to health care providers in Europe and the Commonwealth of Independent States (“Europe CIS”) improved 22% to R8,5 billion. The acquisition of Mono-Embolex, a thrombolytic product with almost all of its sales in Germany, in the second half of the previous year further strengthened Aspen’s portfolio in this therapeutic area.   In Latin America (excluding Venezuela), revenue to customers increased 3% to R3,5 billion. Nutritional sales were the growth driver, increasing 18% and Infacare was successfully launched in Mexico, securing an important government tender. Aspen has suspended trade in Venezuela pending an improvement in the economic conditions.   Sales to customers in the North America and the Middle East North Africa territories increased strongly off relatively low bases, growing by 42% and 51% respectively.   Manufacturing revenue continued to advance with particularly strong growth in active pharmaceutical ingredient (“API”) sales of 19% to R4,0 billion.   The installation of a new high speed pre-filled syringe filling line at Aspen Notre Dame de Bondeville was completed during the period and commercial production is underway. At Aspen Oss the capital expenditure projects include adding new production capabilities and maintaining the sustainability of the site.   SOUTH AFRICAN BUSINESS Comparable revenue in South Africa was down 1% at R8,1 billion. Nutritionals products maintained their growth momentum, adding 11% to revenue and there were impressive increases in manufacturing revenue for both APIs (+52%)

Aspen’s profit after tax increases by 35% Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical manufacturer in the southern hemisphere, has announced pleasing results for the six months ended 31 December 2015. The Group delivered solid growth in a period marked by economic stress and weakening market currencies. The factors set out below have significantly affected the comparability of the results with those of the prior period: The completion on 31 August 2015 of the divestment of the generics business conducted in Australia as well as certain branded products distributed in Australia to Strides group companies, the related termination of license arrangements in Australia and the completion on 1 October 2015 of the divestment of a portfolio of products distributed in South Africa to Litha Pharma (collectively “the Divestments”). The Divestments gave rise to a pre-tax profit on disposal of R1.7 billion. However, as a consequence of the timing of these transactions, the contribution to the trading results by the Divestments is substantially reduced in the current period. In the period from 1 July 2015 until the effective date of divestment, revenue from the Divestments was R202 million whereas revenue from the Divestments for the six months ended 31 December 2014 was R1 148 million. The economic situation in Venezuela deteriorated over the 6 months to December 2015 and the Venezuelan authorities have increasingly limited authorisations to pay for pharmaceutical imports using the official CENCOEX rate during this period of Venezuelan Bolivars (“VEF”) 6.30 per US Dollar (“USD”). As a consequence of the limited payment approvals and the uncertain economic and political situation in Venezuela, the Group has concluded that it would be more appropriate to apply the SIMADI exchange rate of VEF 200 per USD to report the Venezuelan business’ financial position, results of its operations and cash flows for the 6 months ended 31 December 2015. This has resulted in a one-off currency devaluation loss on foreign denominated liabilities of R841million. The profit arising from the Divestments, the currency devaluation loss and the hyperinflationary adjustments relating to Venezuela are excluded in determining normalised headline earnings per share (“NHEPS”) which increased by 14%. In order to provide meaningful comparability of the financial performance of the ongoing underlying business, a measure described as comparable NHEPS has been determined by removing the contribution by the Divestments from NHEPS and including the results of Aspen’s business in Venezuela translated at VEF 200 per USD in the prior reporting period. Comparable NHEPS for the 6 months ended 31 December 2015 was 640,9 cents, an increase of 21%. Applying the same principles, comparable revenue increased by 8% and comparable operating profit increased by 8%. GROUP PERFORMANCE Revenue excluding the effect of the Divestments, increased by 8% to R 17.3 billion. Profit after tax increased 35% to R3.3 billion. Comparable normalised headline earnings per share increased by 21% to 640,9 cents. Normalised headline earnings per share improved by 14% to 655.5 cents. Borrowings, net of cash, increased R3.5 billion over the period to R33.5 billion. Group operating cash flows were negatively affected by a R1.8 billion increase in working capital over the period. Stephen Saad, Aspen Group Chief Executive said, “Performance was led by the International business where the Europe CIS region made a strong contribution. The nutritional products in South Africa and in Asia Pacific also achieved good growth. The completion of the Divestments marks an important step in achieving increased focus in the South African and Asia Pacific businesses. Further meaningful advances in the implementation of Aspen’s strategic objectives have been made and we are seeking to grow the business in targeted therapeutic categories. We remain alert to opportunities to expand our product portfolio in these areas of focus.” INTERNATIONAL BUSINESS The International Business improved revenue 2% to R9.0 billion and raised operating profit before amortisation, adjusted for specific non-trading items (“EBITA”), 16% to R2.8 billion. Revenue was unfavourably affected by R836 million due to the devaluation of the Venezuelan contribution. Excluding the effect of the devaluation, revenue increased 14% in the remainder of the International business. Revenue from customers in Europe and the Commonwealth of Independent States (“Europe CIS”) increased 21% to R6.1 billion. Finished dose form pharmaceutical sales to healthcare providers were up 20% to R4.1 billion. The acquisition of Mono-Embolex, with almost all of its sales in Germany, in the second half of the previous year further strengthened Aspen’s offering in this therapeutic area and added to growth. However, the contribution from Russia fell sharply due to the significant weakening of the Ruble. API sales continued to grow and were the largest part of the balance of the revenue from Europe CIS. Sales to customers in Latin America (excluding Venezuela) declined by 1% to R1.7 billion, unfavourably influenced by difficult socio-economic conditions in Brazil. The nutritionals products in the region maintained their positive growth momentum with revenue rising 12%. Demand for Aspen’s pharmaceutical products was strong, but performance has continued to be suppressed by unreliable supply of certain key products by contract manufacturers. The devalued contribution from Venezuela is no longer material to the Group.| Sales to customers in the Rest of the World increased 4% to R922 million, led by a positive performance in the Middle East North Africa territory. The installation of a new high-speed pre-filled syringe filling line at Aspen Notre Dame de Bondeville (“Aspen NDB”) was completed during the period and commercial production is about to commence. At Aspen Oss capital expenditure projects are ongoing, focused on the sustainability of the site. SOUTH AFRICAN BUSINESS In the South African business revenue was 3% lower at R4.2 billion. Excluding the effect of the Divestments, revenue improved by 4%. The nutritionals products were the leading performer, with revenue growing 15% to R402 million. In the balance of the private sector, branded and generic pharmaceuticals performed satisfactorily. However, supply problems severely undermined the performance of the over-the-counter (“OTC”) products with a consequential decline in key OTC brands. Sales in the public sector (excluding

Aspen’s half-year gross revenue surges by 47% to R19 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the fifth largest generic company in the world, has announced stellar results for the six months ended 31 December 2014, which have primarily been driven by its offshore businesses. GROUP PERFORMANCE Gross revenue increased by 47% to R19.0 billion. Operating profit rose by 50% to R4.3 billion. Net profit after tax and earnings per share each advanced 27% to R2.5 billion and 539 cents respectively. Normalised headline earnings, being headline earnings adjusted for specific non-trading items, increased by 22% to R2.6 billion. Normalised headline earnings per share improved by 22% to 569 cents. Borrowings net of cash reduced by R1.2 billion while cash generated from operating activities accelerated 128%. Stephen Saad, Aspen Group Chief Executive said, “We are pleased with the Group’s excellent performance. These results were underpinned by the expansion of our International business, which now contributes 46% to the Group’s gross revenue. The Nutritionals products have also made an increased contribution to the Group..” “The global pharmaceutical industry is experiencing a prevalence of restructuring and consolidation, which creates acquisitive opportunities. Aspen is well placed to participate in these and its proven capability to successfully execute complex multi-territory transactions makes Aspen a strong candidate for such opportunities,” said Saad INTERNATIONAL BUSINESS Revenue in the International business was 158% higher at R8.8 billion and performance was boosted by the inclusion of the significant transactions completed during the previous financial year. Revenue from the Europe CIS business climbed 229% to R5.1 billion from finished dose form pharmaceuticals and active pharmaceutical ingredient sales. Revenue in Latin America advanced 118% to R2.6 billion, largely driven by the recent infant milk formula acquisition, while sales to customers in the Rest of the World were up 36% to R0.9 billion. Capital expenditure projects are continuing at Aspen Oss in the Netherlands and at the French-based Aspen Notre Dame de Bondeville site. ASIA PACIFIC BUSINESS Revenue in the Asia Pacific region was 3% higher at R4.4 billion where the Nutritionals products led the way with strong double-digit growth. Sales to customers in Asia continued on an impressive growth trajectory, doubling to R0.6 billion.  SOUTH AFRICAN BUSINESS As the ongoing leading pharmaceutical manufacturer in the country, revenue in the South African business grew by 12% to R4.3 billion. Private sector pharmaceutical sales increased 10% through a combination of organic growth and new product launches. Sales in the public sector were flat. The consumer division raised revenue by 30%, led by the Nutritionals products with Infacare achieving an increase in its share of this category. The capital expenditure projects at the Port Elizabeth finished dose form manufacturing site and the Cape Town API manufacturing site are progressing well. SUB-SAHARAN BUSINESS In Sub-Saharan Africa, revenue improved by 5% to R1.5 billion. Margin improvement initiatives yielded positive results and lifted EBITA 12% to R210 million.     Issued by:         Shauneen Beukes, Shauneen Beukes Communications Tel: +27 (012) 661-8467 : Cell: +27 82 389 8900   Disclaimer We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “believe”, “anticipate”, “expect”, “intend”, “seek”, “will”, “plan”, “indicate, “could”, “may”, “endeavor”, “prospects” and “project” and similar expressions are intended to identify such forward looking statements, but are not the exclusive means of identifying such statements. By their very nature, forward looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that predictions, forecasts, projections and other forward looking statements will not be achieved. If one or more of these risks materialize, or should underlying assumptions prove incorrect, actual results may be very different from those anticipated. The factors that could cause our actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward looking statements are discussed in each year’s annual report. Forward looking statements apply only as of the date on which they are made, and we do not undertake other than in terms of the Listings Requirements of the JSE Limited, any obligation to update or revise any of them, whether as a result of new information, future events or otherwise. All profit forecasts published in this report are unaudited.

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the fifth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the year ended 30 June 2014. GROUP PERFORMANCE Revenue increased by 53% to R29.5 billion. Operating profit rose by 47% to R7.4 billion. Normalised headline earnings, being headline earnings adjusted for specific non-trading items, was up 27% to R4.9 billion. Normalised headline earnings per share advanced 27% to 1064 cents. A capital distribution of 188 cents per ordinary share was declared by way of a capital reduction payable out of contributed tax capital to shareholders. Stephen Saad, Aspen Group Chief Executive said, “The Board is pleased with the Group’s performance, particularly that of the International business which was the most significant growth driver and the largest business segment contributor to revenue and to operating profit.  Accelerated revenue from Latin America bodes well for that region while Asia remains an important growth territory. The South African business continues to retain its position as the leading pharmaceutical company in the private and public sectors of this market, and Sub-Saharan Africa also delivered a pleasing performance.” SIGNIFICANT TRANSACTIONS A number of significant transactions were completed during the financial year and were influential in the performance of the Group.  These transactions have created important new opportunities for Aspen in both product offering and geographic coverage.  The key terms of these transactions are set out below: The acquisition of the active pharmaceutical ingredient (“API”) manufacturing business, primarily in the Netherlands, from MSD for EUR 31 million net of cash acquired, became effective 1 October 2013 and trades as Aspen Oss and Aspen API. The acquisition of a portfolio of 11 branded finished dose form molecules from MSD in a related transaction for USD 600 million, of which USD 67 million is subject to delayed payment terms, became effective on 31 December 2013. The acquisition of the Arixtra and Fraxiparine/Fraxodi thrombolytic brands worldwide (excluding China, India and Pakistan) from GlaxoSmithKline (“GSK”) for GBP 505 million became effective on 31 December 2013. In a connected transaction which became effective on 30 April 2014, a further GBP 194 million was paid to GSK for the acquisition of the specialised sterile production site in France which manufactures these brands and the related inventory. This business trades as Aspen Notre Dame de Bondeville (“Aspen NDB”). The acquisition from Nestlé of certain licence rights to infant nutritional intellectual property, net assets, including a production facility in Mexico, and shares in infant nutritional businesses in several countries in Latin America for a purchase consideration of USD180 million was completed with effect from 28 October 2013. The acquisition from Nestlé of certain rights to intellectual property licenses and net assets of the infant nutritionals business previously conducted by Pfizer in certain southern African territories, including South Africa, was approved by the competition authorities and became effective on 27 January 2014. The purchase consideration for this transaction of USD 43 million was prepaid in the prior financial year. INTERNATIONAL BUSINESS The International business advanced revenue 242% to R12.7 billion and increased operating profit before amortisation, adjusted for specific non-trading items (“EBITA”), 144% to R3.6 billion.  The margin percentage in the International business narrowed as a consequence of lower margin rates in the Aspen Oss business and in the infant nutritional business in Latin America acquired during the year.  The International business gained most from the significant transactions completed during the financial year and contributed 40% of Group gross revenue and 47% of Group EBITA.  Performance was also boosted by organic growth from the pre-existing global brands portfolio. With effect from 1 January 2014 Aspen introduced a specialised sales and marketing team into Europe and the Commonwealth of Independent States (formerly the Soviet Union) (“CIS”) for the first time. Aspen now has a substantial footprint across Europe and the CIS with more than 400 active sales and marketing focused personnel in 18 countries, the majority of whom transferred from GSK in terms of the arrangements under the acquisition of Arixtra and Fraxiparine. Revenue from customers in Europe CIS was over 5 times greater than the prior year at R7.2 billion.  Of this amount, R4.0 billion was derived from sales of finished dose form pharmaceuticals to healthcare providers and the major portion of the balance was from sales of APIs. There was also a strong acceleration of revenue from customers in Latin America where sales climbed 122% to R3.5 billion.  The acquisitions made by the Group accounted for the largest portion of this increase despite some supply issues, supported by good performances in Mexico and Venezuela. In the Rest of the World, sales to customers were up 181% to R1.7 billion influenced by an increased exposure to the US resulting from the acquisitions concluded during the year and by positive progress in the Middle East North Africa territory. Significant activity has been undertaken at the Aspen Oss API manufacturing site and also at the Aspen NDB specialist sterile manufacturing site.  At both of these sites it has been necessary to disentangle the manufacturing operations from the systems of the vendors.  Capital expenditure projects are also ongoing at both these sites.  At Aspen Oss, improvements to the safety profile of the site are receiving urgent attention and at Aspen NDB, additional capacity is being added with the construction of an entirely new production area. On 10 September 2014, Aspen Global Incorporated (“AGI”) entered into an agreement with Mylan Ireland Limited (“Mylan”) in terms of which AGI will dispose of its rights to commercialise the fondaparinux products it recently acquired from GSK (being Arixtra and the authorised generic thereof) in the United States (“US”) to Mylan. AGI will also enter into a supply agreement to supply these fondaparinux products to Mylan on specified terms.  The transaction will complete upon the satisfaction of certain conditions precedent, including regulatory approvals.  Mylan will pay Aspen USD 225 million upon completion of the transaction. An additional USD 75 million will be held in escrow and

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the ninth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the six months ended 31 December 2013. Group Performance Revenue increased by 33% to R12.0 billion. Operating profit improved by 16% to R2.9 billion after absorbing transaction costs of R143 million relating to the significant new business acquisitions undertaken in the reporting period. Normalised headline earnings, being headline earnings adjusted for specific non-trading items, rose 23% to R2.1 billion. Normalised diluted headline earnings per share increased by 23% to 467.4 cents. Stephen Saad, Aspen Group Chief Executive said, “The business delivered pleasing returns with the International business leading the Group’s growth with significant advances in revenue and profits through a combination of organic growth and the contribution of completed acquisitions. This momentum is expected to continue as Aspen further extends its emerging market presence to the Commonwealth of Independent States (“CIS”) comprising Russia and the former Soviet Republics, to Central and Eastern Europe (“CEE”) as well as adding to its existing business in Asia and Latin America.” RECENT TRANSACTIONS Aspen has recently undertaken extensive corporate activity which will transform the Group. The following is the status of the material transactions involved: The acquisition of the Active Pharmaceutical Ingredient (“API”) manufacturing business, primarily in the Netherlands, from MSD for EUR31 million plus the value of inventory, became effective on 1 October 2013. The acquisition of a portfolio of 11 branded finished dose form molecules from MSD in a related transaction for USD600 million, of which USD67 million has delayed payment terms, became effective on 31 December 2013. The acquisition of the Arixtra and Fraxiparine/Fraxodi brands worldwide (excluding China, India and Pakistan) from GSK for GBP505 million became effective on 31 December 2013. In a related transaction, a further GBP100 million and EUR113 million has been paid into escrow in respect of the acquisition of the specialised sterile production site in France which manufactures these brands and the related inventory. This transaction is scheduled to become effective on 30 April 2014. The acquisition of certain licence rights to infant nutritional intellectual property, net assets, including a production facility in Mexico, and shares in infant nutritional businesses in several countries in Latin America from Nestlé for a purchase consideration of USD180 million was completed with effect from 28 October 2013. The acquisition from Nestlé of certain rights to intellectual property licenses and net assets of the infant nutritionals business presently conducted by Pfizer in certain southern African territories, including South Africa, has been approved by the competition authorities and became effective on 27 January 2014. SOUTH AFRICAN BUSINESS In the South African business, revenue improved by 8% to R3.8 billion and operating profit before amortisation, adjusted for specific non-trading items (“EBITA”) was unchanged at almost R1.0 billion. Revenue in the Pharmaceutical division advanced 7% to R3.2 billion. In the private sector, double digit percentage growth in revenue was delivered through a combination of solid organic growth and the contribution from new product launches. Aspen grew ahead of the market in all segments of the private sector. In the public sector, significantly reduced prices for antiretrovirals (“ARVs”) and a reduced share of the ARV tender gave rise to revenue contraction which limited the overall performance of the Pharmaceutical division. The decrease in ARV prices, the continued weakening of the Rand and rising inflation in administered costs caused a reduction in margin percentages despite gains achieved in production efficiency and procurement. The Consumer division raised revenue by 14% which was a positive outcome given the economic pressures at play in the retail sector. The Group continued to invest in capital expansion projects to enhance production capacities and capabilities in South Africa. The two major projects underway are the extension of production facilities at Fine Chemicals Corporation in Cape Town which will allow this site to contribute meaningfully to Aspen’s expanded API activities, and the building of the high containment suite in Port Elizabeth which will further strengthen the Group’s strategic manufacturing capabilities. ASIA PACIFIC BUSINESS The region’s record of unbroken growth since inception in 2001 was extended with a rise of 27% in revenue to R4.3 billion supported by products added as a consequence of acquisitions by the Group in the previous financial year. EBITA was up by 4% to almost R1.0 billion as most of the products added to the portfolio were at the lower margins available for distribution services and the ongoing mandated price cuts in Australia weighed on profits. The margin percentage contraction was cushioned by savings achieved in the cost of goods and through a reduction in rebates paid. In Asia, Aspen’s newly established businesses in the Philippines, Malaysia and Taiwan made impressive advances albeit off a low base. Sales to customers in Asian countries increased by 22% to R311 million. INTERNATIONAL BUSINESS The International business led growth in the Group with revenue increasing 94% to R3.4 billion and EBITA rising 79% to R1.1 billion. The acquisition of the API business from MSD effective 1 October 2013 and the completion of the infant nutritional transaction with Nestlé effective 28 October 2013 together added R1.3 billion to revenue at low margins, boosting the sales growth and lowering overall margin percentages. These deals were also influencing factors in the rise in sales to customers in the Latin American (up 60% to R1.2 billion) and Rest of World (up 147% to R2.2 billion) territories. The global brands portfolio was an important driver of the growth achieved in the International business and the margin improvement projects for these products continued to yield favourable outcomes. Contributions from certain territories in this business have also benefitted from relative currency strength against the Rand. SUB SAHARAN AFRICA BUSINESS In Sub Saharan Africa gross revenue advanced by 41% to R1.4 billion while EBITA climbed 53% to R0.2 billion as the good momentum achieved in the second half of the prior year was maintained. PROSPECTS The completion of the recent transactions